10x Genomics Reports Q2 Growth Amid Challenges

Q2 2024 Performance Overview

10x Genomics Inc., a company at the forefront of biotechnology innovation, reported its second-quarter 2024 revenue at $153 million, marking a 4% increase compared to the previous year. This growth is particularly notable given the broader macroeconomic challenges currently affecting many industries. Despite the positive trend in revenue, the company has made a strategic decision to revise its full-year revenue guidance down to $640-$660 million. This revision acknowledges slower-than-expected sales in its instrument segment, including the Xenium platform.